Magdalena Lason-Tyburkiewicz
Overview
Explore the profile of Magdalena Lason-Tyburkiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Depoortere R, Papp M, Gruca P, Lason-Tyburkiewicz M, Niemczyk M, Varney M, et al.
J Psychopharmacol
. 2019 Jul;
33(11):1456-1466.
PMID: 31290370
Background: NLX-101 (also known as F15599) is a highly selective and efficacious 'biased' agonist at cortical 5-hydroxytryptamine 1A (5-HT) heteroreceptors. In rodents, it possesses marked antidepressant-like activity, potently and completely...
2.
Rossetti A, Paladini M, Colombo M, Gruca P, Lason-Tyburkiewicz M, Tota-Glowczyk K, et al.
Int J Neuropsychopharmacol
. 2018 May;
21(9):883-893.
PMID: 29788232
Background: Psychiatric disorders are associated with altered function of inhibitory neurotransmission within the limbic system, which may be due to the vulnerability of selective neuronal subtypes to challenging environmental conditions,...
3.
Papp M, Gruca P, Lason-Tyburkiewicz M, Litwa E, Niemczyk M, Tota-Glowczyk K, et al.
Behav Pharmacol
. 2018 Mar;
29(6):537-542.
PMID: 29537988
We have previously reported the effects of intracranial injections of dopamine D1, D2 and D3 ligands in animals subjected to the Novel Object Recognition (NOR) test following exposure to chronic...
4.
Papp M, Gruca P, Lason-Tyburkiewicz M, Litwa E, Niemczyk M, Tota-Glowczyk K, et al.
Psychopharmacology (Berl)
. 2017 Jun;
234(17):2571-2585.
PMID: 28567697
Cognitive deficits in depression can be modelled using the novel object recognition (NOR) test, performance in which is impaired by chronic mild stress (CMS). We aimed to examine the involvement...
5.
Calabrese F, Brivio P, Gruca P, Lason-Tyburkiewicz M, Papp M, Riva M
ACS Chem Neurosci
. 2017 Jan;
8(4):817-825.
PMID: 28094500
Depression, a major cause of disability worldwide, is characterized by a complex and heterogeneous symptomatology. With this respect, cognitive deterioration represents a major problem that has a strong impact on...
6.
Papp M, Gruca P, Lason-Tyburkiewicz M, Willner P
Behav Pharmacol
. 2016 Oct;
28(1):1-8.
PMID: 27759570
Ketamine is the prototype of a new generation of antidepressant drugs, which is reported in clinical studies to be effective in treatment-resistant patients, with an effect that appears within hours...
7.
Wozniak M, Acher F, Marciniak M, Lason-Tyburkiewicz M, Gruca P, Papp M, et al.
Curr Neuropharmacol
. 2016 Jan;
14(5):413-26.
PMID: 26769224
Considering that ligands of metabotropic glutamate and GABA receptors may exert beneficial effects on schizophrenia, we assessed the actions of the first mGlu>4-selective orthosteric agonist, LSP4-2022, in several tests reflecting...
8.
Papp M, Gruca P, Lason-Tyburkiewicz M, Willner P
Psychopharmacology (Berl)
. 2016 Jan;
233(7):1235-43.
PMID: 26769042
Background: The treatment of depression in old age is complicated by frequent co-morbidity with cognitive impairment. Anti-dementia drugs have some efficacy to improve cognitive performance and there is an inconsistent...
9.
mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia
Wieronska J, Kleczek N, Wozniak M, Gruca P, Lason-Tyburkiewicz M, Papp M, et al.
Neurochem Int
. 2015 Apr;
88:97-109.
PMID: 25863284
Diverse preclinical studies exploiting the modulation of the GABAergic and/or glutamatergic system in brain via metabotropic receptors suggest their potential therapeutic utility. GS39783 and CDPPB, positive allosteric modulators of GABAB...
10.
Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyan I
Behav Pharmacol
. 2014 Aug;
25(5-6):567-74.
PMID: 25083572
The aim of this study was to evaluate whether chronic treatment with cariprazine, a dopamine D2 and D3 receptor partial agonist with preferential binding to D3 receptors, shows antidepressant-like effects...